Responding to emerging COVID-19 variants of concern

AI Summary

This document details a collaborative initiative led by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the Antivirals and Therapeutics Taskforce of the Department of Health and Social Care (DHSC), the UKHSA, and academic experts. On September 12, 2022, these organizations held a workshop to address critical challenges in the management of the SARS-CoV-2 pandemic. The primary issue identified was the rapid evolution of viral variants, which has led to viral escape mechanisms and a significant loss of activity in existing antiviral drugs and monoclonal antibodies (mAbs). These mutations create a major regulatory and clinical hurdle: the inability to generate traditional efficacy data at a speed that matches the emergence of new strains. To overcome this, the regulatory framework established through these discussions focuses on leveraging in vitro data and Pharmacokinetic-Pharmacodynamic (PK-PD) analysis. This framework is designed to assist industry stakeholders and product developers in evaluating the ongoing effectiveness of therapeutic agents. Required actions for developers include utilizing these advanced analytical models to bridge knowledge gaps and support the rapid deployment of treatments. By shifting toward these predictive evaluations, the MHRA and its partners aim to provide a more responsive pathway for maintaining the efficacy of treatments against a constantly changing viral landscape.